StockData
Amgen Inc logo

Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen GAAP Operating Margin as % of Product Sales by Year

GAAP Operating Margin as % of Product Sales (%) (%)

Amgen GAAP Operating Margin as % of Product Sales: 25.8% in FY2025, up 3.1 pts from a year earlier.

Latest, FY2025
25.8%
Period ended Dec 31, 2025
Change on a year earlier
+3.1 pts
22.7% in FY2024
History
9 years
Since FY2017
Sources
8
Documents cited below

Where the FY2025 figure comes from

“|| GAAP operating income as a percentage of product sales | 29.0 | % | 26.5 | % | 25.8 | % | 22.7 | %”

Source: Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗

Reported in Form 8-K Reconciliations of GAAP to Non-GAAP Measures.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Cite this data

StockData. (2026). Amgen GAAP Operating Margin as % of Product Sales (%), annual FY2017–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/gaap-op-margin

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.